缺血性卒中急性期他汀类药物治疗对血清超敏C-反应蛋白影响及预后评价

The effect of statin therapy for acute ischemic stroke on high-sensitivity C-reactive protein and the prognosis

对他汀类药物治疗组（他汀治疗组）或非他汀类药物治疗组（对照组）患者入院时和发病30 d时临床资料进行分析,并比较两组血清超敏C-反应蛋白水平的变化.结果显示,他汀治疗组患者发病30 d时血清超敏C-反应蛋白低于对照组（t=9.925,P=0.015）,发病后3个月预后优于对照组（χ2=4.762,P=0.029）;经逐步Logistic回归分析,入院时美国国立卫生研究院卒中量表评分（OR=1.383,95％CI：1.062 ～ 1.800;P=0.028）和发病48 h血清超敏C-反应蛋白水平（OR=1.472,95％CI：0.500～4.370;P=0.001）对患者发病3个月时的预后具有独立预测作用.提示他汀类药物可以降低急性缺血性卒中患者血清超敏C-反应蛋白水平,对发病3个月时的预后具有预测作用.

The clinical data of 100 patients with acute ischemic stroke on admission and 30 d after stroke were analyzed.The patients were evenly divided into 2 groups （statin group and control group）.Serum high-sensitivity C-reactive protein （hs-CRP） level was similar in the 2 groups within 48 h after onset,but was significantly lower in statin group 30 d after onset （t =9.925,P =0.015）.The statin group also had better 3-month outcome （χ2=4.762,P =0.029）.After using stepwise Logistic regression analysis,only National Institute of Health Stroke Scale （NIHSS） score on admission （OR =1.383,95%CI：1.062-1.800; P =0.028） and hs-CRP in the acute phase （OR =1.472,95%CI：0.500-4.370; P =0.001） were significantly and independently predictive for 3-month outcome.This study indicates that statin therapy reduces hs-CRP level in the acute phase and can predict the 3-month clinical outcome of ischemic stroke.